Testing two medications together for newly diagnosed T-cell lymphoma

This trial is testing whether combining two medications — Duvelisib and Chidamide — can help treat people with newly diagnosed peripheral T-cell lymphoma, a rare blood cancer. Researchers want to see if this combination works better than existing treatments. You would take these medications for two cycles (8 weeks total) to see how well they work for you.

Peripheral T-cell lymphoma is a rare and serious blood cancer that is difficult to treat. Doctors are looking for new treatment combinations that might be more effective and help patients live longer and healthier lives.